EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Burden of Pancreatic Cancer From Asia in 2022 and Predictions to 2050 According to GLOBOCAN Estimates

Lin‐Kang Zhao, Jing Tu, Hong‐Xia Zuo, Fu‐Qiang Yin, Teng‐Yu Gao, Lu Meng, Long‐Chuan Xie, Chao Zhang

Gut Medicine · 2025

DOI: 10.1002/gtm2.70001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gut Medicine, 2025. Verfasst von Lin‐Kang Zhao und 7 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer is a malignant tumor with high incidence and mortality, which imposes a significant burden on individuals, families and the society. This study evaluates the regional burden and epidemiological trends of pancreatic cancer from Asia in 2022, and predicts the incidence and mortality trends in the next 30 years.

Methods

A series of data on the number of new pancreatic cancer cases and death population estimated in 2022 are retrieved from GLOBOCAN 2022 database, using the world standard method of calculating age‐standardized rates. This study analyzes the burden and epidemiological trends of pancreatic cancer in 48 countries in Asia from four aspects. It predicts the incidence and mortality for the next 30 years.

Results

The incidence of pancreatic cancer in each country is roughly proportional to mortality and Human Development Index. Both in terms of incidence and mortality, Japan bears the highest burden, whereas Pakistan has the lowest burden. In the whole age group, the incidence of pancreatic cancer is mainly concentrated in males and middle‐aged or elderly people, but in Japan and South Korea, due to other risk factors (diet, obesity, occupational factors, etc.), the incidence of pancreatic cancer is mainly concentrated in women. Up to 2050, 487,000 new cases of pancreatic cancer and 459,000 new deaths from pancreatic cancer are expected to occur.

Conclusion

The observed trends and predictions indicate that the burden of pancreatic cancer will continue to increase, especially in economically developed regions. It is recommended that in high‐risk countries, tobacco control, alcohol restriction, promotion of physical examinations and physical exercise be initiated as early as possible, and a regional monitoring network should be established, with a focus on screening high‐risk groups (such as those with long‐term obesity and smoking) to stabilize the incidence and mortality indicators. Trial Registration This is a cross‐sectional study derived from the GLOBOCAN database. Therefore, clinical trial registration was not conducted

Zitieren

APA

Zhao, L., Tu, J., Zuo, H., Yin, F., Gao, T., Meng, L., Xie, L., & Zhang, C. (2025). The Burden of Pancreatic Cancer From Asia in 2022 and Predictions to 2050 According to GLOBOCAN Estimates. Gut Medicine. https://doi.org/10.1002/gtm2.70001

Vancouver

Zhao L, Tu J, Zuo H, Yin F, Gao T, Meng L, et al. The Burden of Pancreatic Cancer From Asia in 2022 and Predictions to 2050 According to GLOBOCAN Estimates. Gut Medicine. 2025. doi:10.1002/gtm2.70001

BibTeX
@article{Zhao2025,
  author = {Zhao, Lin‐Kang and Tu, Jing and Zuo, Hong‐Xia and Yin, Fu‐Qiang and Gao, Teng‐Yu and Meng, Lu and Xie, Long‐Chuan and Zhang, Chao},
  title = {The Burden of Pancreatic Cancer From Asia in 2022 and Predictions to 2050 According to GLOBOCAN Estimates},
  journal = {Gut Medicine},
  year = {2025},
  doi = {10.1002/gtm2.70001}
}
Kostenlos starten →